Product Description
Mimic of miR29a; for the treatment of tennis elbow (lateral epicondylitis) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04670289)
Mechanisms of Action: miR-29 Replacer
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Causeway Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tennis Elbow
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06192927 |
CWT-TE2 | P2 |
Completed |
Tennis Elbow |
2025-03-03 |
50% |
2025-08-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/28/2025 |
News Article |
Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis |
|
02/15/2023 |
PubMed |
The pandemic and changes in early career researchers' career prospects, research and publishing practices. |
|
02/01/2022 |
PubMed |
Relationship of fasting glucose and longitudinal Alzheimer's disease imaging markers. |
|
06/21/2021 |
News Article |
New Therapeutic Drugs for Tendinitis Treatment Coming Down the Pipeline |
|
03/11/2020 |
PubMed |
Data sharing, management, use, and reuse: Practices and perceptions of scientists worldwide. |